Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-04-10
2007-04-10
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S586000, C548S568000, C564S027000
Reexamination Certificate
active
10976067
ABSTRACT:
Certain α-, β-, and γ-amino acid derivatives are disclosed as selective GlyT2 inhibitors for the treatment of central nervous system (CNS) conditions such as muscle spasticity, tinnitus, epilepsy and neuropathic pain.
REFERENCES:
patent: 6057338 (2000-05-01), Yang et al.
patent: 6063796 (2000-05-01), Yang et al.
patent: 2 838 739 (2003-10-01), None
patent: WO 99/34790 (1999-07-01), None
patent: WO 00/71507 (2000-11-01), None
patent: WO 02/64135 (2002-08-01), None
Berk, S.C. et al. A Combinatorial Approach toward the Discovery of Non-Peptide Subtype-Selective Somatostatin Receptor Ligans. J. Comb. Chem. 1999, 1(5):388-396.
Evans, J. et al. Cloning, Functional Characterization and Population Analysis of a Variant Form of the Human Glycine Type 2 Transporter. FEBS Lett. 1999, 463(3):301-306.
Friauf, E. et al. Developmental Expression of the Glycine Transporter GLYT2 in the Auditory System of Rats Suggests Involvement in Synapse Maturation. J. Comp. Neurol. 1999, 412(1):17-37.
Gallagher, M.J. et al. Characterization of Multiple Forms of the Human Glycine Transporter Type-2. Mol. Brain Res. 1999, 70(1):101-115.
Geerlings, A. et al. Characterization of the Interactions Between the Glycine Transporters GLYT1 and GLYT2 and the SNARE protein syntaxin 1A. FEBS Letters 2000, 470:51-54.
Grenningloh, G. et al. The Strychnine-binding Subunit of the Glycine Receptor Shows Homology with Nicotinic Acetylcholine Receptors. Nature (London) 1987, 328(16):215-220.
Guastella, J. et al. Cloning, Expression, and Localization of a Rat Brain High-Affinity Glycine Transporter. Proc. Natl. Acad. Sci. U.S.A. 1992, 89(15):7189-7193.
Huang, W. and R.K. Simpson. Long-term Intrathecal Administration of Glycine Prevents Mechanical Hyperalgesia in a Rat Model of Neuropathic Pain. Neurol. Res. 2000, 22:160-164.
Isaac, M. Synthesis and Structure Activity Relationship of Novel Chiral Ligans for the Glycine-Reuptake Transporter Type-2 (GlyT-2). Abstracts of Papers, 228th ACS National Meeting, Philadelphia, PA, U.S., Aug. 22-26, 2004.
Iversen, L.L. Role of Transmitter Uptake Mechanism in Synaptic Neurotransmission. Br. J. Pharmacol. 1971, 41(4):571-591.
Krnjevic, K. Chemical Nature of Synaptic Transmission in Vertebrates. Physiol. Rev. 1974, 54(2):418-540.
Liu, Q-R. et al. Cloning and Expression of a Spinal Cord- and Brian-Specific Glycine Transporter with Novel Structural Features. J. Biol. Chem. 1993, 268(30):22802-22808.
Lopez-Corcuera, B. et al. Differential Properties of Two Stably Expressed Brain-Specific Glycine Transporters. J. Neurochem. 1998, 71(5):2211-2219.
Luque, J.M. et al. Cellular Expression of Glycine Transporter 2 Messenger RNA Exclusively in Rat Hindbrain and Spinal Cord. Neuroscience 1995, 64(2):525-535.
Ponce, J. et al. Transmembrane Domaine III Plays an Important Role in Ion Binging and Permeation in the Glycine Tranporter GLYT2. J. Biol. Chem. 2000, 275(18):13856-13862.
Probst, A. et al. The Distribution of Glycine Receptors in the Human Brain. A Light Microscopic Autoradiographic Study Using [3H]Strychnine. Neuroscience 1986, 17(1):11-35.
Raiteri, L. et al. Glycine Taken Up Through GLYT1 and GLYT2 Heterotransporters into Glutamatergic Axon Terminals of Mouse Spinal Cord Elicits Release of Glutamate by Homo-Transporter Reversal and Through Anion Channels. Biochem. Pharm. 2005, 69(1):159-168.
Rajendra, S. and P.R. Schofield. Molecular Mechanisms of Inherited Startle Syndromes. Trends Neurosci. 1995, 18(2):80-82.
Simpson, R.K., Jr. et al. Reduction in the Mechanonociceptive Response by Intrathecal Administration of Glycine and Related Compounds. Neurochem. Res. 1996, 21(10):1221-1226.
Young, A.B. and S.H. Snyder. Strychnine Binding Associated with Glycine Receptors of the Central Nervous System. Proc. Natl. Acad. Sci. U.S.A. 1973, 70(10):2832-2836.
Zarbin, M.A. et al. Glycine Receptor: Light Microscopic Autoradiographic Localization with [3H]Strychnine. J. Neurosci. 1981, 1(5):532-547.
Wolin, R.L. et al. Inhibitors of the Glycine Transporter Type-2 (GlyT-2): Synthesis and Biological Activity of Benzoylpiperidine Derivatives. Bioorg. Med. Chem. 2004, 12(16):4511-4532.
Wolin, R.L. et al. Novel Glycine Transporter Type-2 Reuptake Inhibitors. Part 2: b- and g-Amino Acid Derivatives. Bioorg. Med. Chem. 2004, 12(16):4493-4509.
International Search Report dated Mar. 31, 2005, for corresponding application PCT/US2004/036009.
Barclay Tristin K.
Santillán, Jr. Alejandro
Tang Liu Y.
Venkatesan Hariharan
Wolin Ronald L.
Harbour John
Janssen Pharmaceutica N.V.
Nolan Jason M.
LandOfFree
GlyT2 modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with GlyT2 modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and GlyT2 modulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3724464